{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:07:20Z","timestamp":1774343240802,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jbspin.2017.03.002","type":"journal-article","created":{"date-parts":[[2017,3,18]],"date-time":"2017-03-18T18:47:11Z","timestamp":1489862831000},"page":"671-675","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments"],"prefix":"10.1016","volume":"84","author":[{"given":"Ga\u00eblle","family":"Clavel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Moulignier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Semerano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2017.03.002_bib0230","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/ana.20431","article-title":"JC virus granule cell neuronopathy: a novel clinical syndrome distinct from progressive multifocal leukoencephalopathy","volume":"57","author":"Koralnik","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0235","doi-asserted-by":"crossref","first-page":"3761","DOI":"10.1002\/art.24966","article-title":"Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases","volume":"60","author":"Molloy","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0240","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/13550280390195388","article-title":"Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian registry investigative neuro AIDS (IRINA)","volume":"9","author":"Antinori","year":"2003","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0245","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","article-title":"PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease Section","volume":"80","author":"Berger","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0250","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/nrrheum.2014.167","article-title":"Sorting out the risks in progressive multifocal leukoencephalopathy","volume":"11","author":"Calabrese","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0255","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/1756285615602832","article-title":"Progressive multifocal leukeoncephalopathy consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives","volume":"8","author":"Pavlovic","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0260","doi-asserted-by":"crossref","first-page":"583","DOI":"10.4161\/mabs.1.6.9884","article-title":"Monoclonal antibodies and progressive multifocal leukoencephalopathy","volume":"1","author":"Berger","year":"2009","journal-title":"mAbs"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0265","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jbspin.2011.11.002","article-title":"Progressive multifocal leukoencephalopathy in autoimmune diseases","volume":"79","author":"Palazzo","year":"2012","journal-title":"Jt Bone Spine Rev Rhum"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0270","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/acr.21564","article-title":"Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases","volume":"64","author":"Bharat","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0275","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1136\/annrheumdis-2012-201638","article-title":"Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study","volume":"71","author":"Arkema","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0280","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1177\/0961203315622819","article-title":"Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review","volume":"25","author":"Henegar","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0285","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fimmu.2015.00159","article-title":"Immune system involvement in the pathogenesis of JC virus induced PML: what is learned from studies of patients with underlying diseases and therapies as risk factors","volume":"6","author":"Monaco","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0290","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.msard.2016.03.005","article-title":"Re-evaluating the incidence of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"8","author":"Borchardt","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0295","doi-asserted-by":"crossref","first-page":"672","DOI":"10.3389\/fmicb.2016.00672","article-title":"Increased prevalence of human polyomavirus JC viruria in chronic inflammatory rheumatic diseases patients in treatment with anti-TNF\u03b1: a 18-month follow-up study","volume":"7","author":"Rodio","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0300","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/jmv.23525","article-title":"Latent viral infections in young patients with inflammatory diseases treated with biological agents: prevalence of JC virus genotype\u00a02","volume":"85","author":"Comar","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0305","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1001\/archneurol.2011.103","article-title":"Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis","volume":"68","author":"Clifford","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0310","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s00415-016-8217-x","article-title":"Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326\u00a0cases","volume":"263","author":"Maas","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0315","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","article-title":"Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies","volume":"64","author":"Molloy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0320","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s40263-015-0286-3","article-title":"Drug-induced progressive multifocal leukoencephalopathy: a comprehensive analysis of the WHO adverse drug reaction database","volume":"29","author":"Melis","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0325","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1136\/annrheumdis-2013-204978","article-title":"A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab","volume":"73","author":"Ray","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0330","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1007\/s00296-011-2216-0","article-title":"A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature","volume":"32","author":"Ryu","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0335","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1002\/art.27687","article-title":"A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab","volume":"62","author":"Kumar","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0340","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/NRL.0b013e318247b868","article-title":"Progressive multifocal leukoencephalopathy in a patient treated with etanercept","volume":"18","author":"Graff-Radford","year":"2012","journal-title":"Neurologist"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0345","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3109\/s10165-006-0530-2","article-title":"Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis","volume":"17","author":"Yamamoto","year":"2007","journal-title":"Mod Rheumatol Jpn Rheum Assoc"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1871528113666140224103712","article-title":"The risk of progressive multifocal leukoencephalopathy under biological agents used in the treatment of chronic inflammatory diseases","volume":"13","author":"Toussirot","year":"2014","journal-title":"Inflamm Allergy Drug Targets"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0355","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.2169\/internalmedicine.48.1926","article-title":"Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA)","volume":"48","author":"Kobayashi","year":"2009","journal-title":"Intern Med Tokyo Jpn"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0360","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1111\/ajt.12810","article-title":"Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase\u00a0II randomized study","volume":"14","author":"Klintmalm","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/2042098612453849","article-title":"Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps","volume":"3","author":"Zaheer","year":"2012","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0370","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.jaad.2010.05.033","article-title":"Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients","volume":"65","author":"Kothary","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0375","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57\u00a0cases from the research on adverse drug events and reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0380","first-page":"117","article-title":"Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group","volume":"87","author":"McGuigan","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0385","article-title":"Safety of biologic DMARDs in RA patients in real life: A systematic literature review and meta-analyses of biologic registers","author":"de La Forest Divonne","year":"2016","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0390","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13365-016-0449-0","article-title":"Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus","volume":"22","author":"Werner","year":"2016","journal-title":"J Neurovirol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0395","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jbspin.2014.12.010","article-title":"Human polyomavirus JC presence in chronic inflammatory rheumatic diseases patients treated with anti-TNF-\u03b1: evaluation of JC viral loads in urine and plasma samples","volume":"82","author":"Bellizzi","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0400","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1212\/WNL.0000000000002314","article-title":"CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients","volume":"86","author":"Lieberman","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0405","first-page":"495","article-title":"The pathogenesis of progressive multifocal leukoencephalopathy","volume":"12","author":"Berger","year":"2011","journal-title":"Discov Med"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0410","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/ana.21443","article-title":"Detection of JC virus DNA fragments but not proteins in normal brain tissue","volume":"64","author":"Perez-Liz","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0415","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/jmv.1890470306","article-title":"PCR detection of JC virus DNA in brain tissue from patients with and without progressive multifocal leukoencephalopathy","volume":"47","author":"Ferrante","year":"1995","journal-title":"J Med Virol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0420","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1570162X1401151102125319","article-title":"Expression of signaling molecules in progressive multifocal leukoencephalopathy","volume":"14","author":"Wollebo","year":"2016","journal-title":"Curr HIV Res"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0425","doi-asserted-by":"crossref","first-page":"S180","DOI":"10.1086\/344280","article-title":"Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy","volume":"186","author":"Sabath","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0430","doi-asserted-by":"crossref","first-page":"e0160277","DOI":"10.1371\/journal.pone.0160277","article-title":"Natalizumab affects T-cell phenotype in multiple sclerosis: implications for JCV reactivation","volume":"11","author":"Iannetta","year":"2016","journal-title":"Plos One"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0435","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3389\/fimmu.2015.00241","article-title":"B\u00a0cells and progressive multifocal leukoencephalopathy: search for the missing link","volume":"6","author":"Durali","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0440","doi-asserted-by":"crossref","first-page":"e0129694","DOI":"10.1371\/journal.pone.0129694","article-title":"IFN-gamma inhibits JC virus replication in glial cells by suppressing T-antigen expression","volume":"10","author":"De-Simone","year":"2015","journal-title":"Plos One"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0445","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/014107689108400612","article-title":"Spontaneous adverse drug reaction reporting vs event monitoring: a comparison","volume":"84","author":"Fletcher","year":"1991","journal-title":"J R Soc Med"},{"key":"10.1016\/j.jbspin.2017.03.002_bib0450","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/fcp.12247","article-title":"Drug-induced progressive multifocal leukoencephalopathy: a case\/noncase study in the French pharmacovigilance database","volume":"31","author":"Colin","year":"2017","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17300416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X17300416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,19]],"date-time":"2019-09-19T22:54:07Z","timestamp":1568933647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X17300416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S1297319X17300416"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.03.002","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments","name":"articletitle","label":"Article Title"},{"value":"Joint Bone Spine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbspin.2017.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Soci\u00e9t\u00e9 fran\u00e7aise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}